HER2+ subtype breast cancers are more likely to grow faster in comparison to other subtypes and have been associated with a poor prognosis; however, this subtype responds to treatment better, since treatments can specifically target the HER2 gene. This evidence concerns the gene ERBB2 and breast carcinoma.